161 related articles for article (PubMed ID: 20533374)
21. [The treatment of osteoporosis and bone resorption of alveoli with alendronate in rat model].
Wang X; Yang Z; Yu S
Zhonghua Kou Qiang Yi Xue Za Zhi; 2001 May; 36(3):193-6. PubMed ID: 11812340
[TBL] [Abstract][Full Text] [Related]
22. Ghrelin against alendronate-induced gastric damage in rats.
Işeri SO; Sener G; Yüksel M; Contuk G; Cetinel S; Gedik N; Yegen BC
J Endocrinol; 2005 Dec; 187(3):399-406. PubMed ID: 16423819
[TBL] [Abstract][Full Text] [Related]
23. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study.
Millonig G; Graziadei IW; Eichler D; Pfeiffer KP; Finkenstedt G; Muehllechner P; Koenigsrainer A; Margreiter R; Vogel W
Liver Transpl; 2005 Aug; 11(8):960-6. PubMed ID: 16035083
[TBL] [Abstract][Full Text] [Related]
24. Effect of ovariectomy and alendronate on implant osseointegration in rat maxillary bone.
Viera-Negrón YE; Ruan WH; Winger JN; Hou X; Sharawy MM; Borke JL
J Oral Implantol; 2008; 34(2):76-82. PubMed ID: 18478902
[TBL] [Abstract][Full Text] [Related]
25. Gastroresistant microparticles containing sodium alendronate prevent the bone loss in ovariectomized rats.
Cruz L; Assumpção E; Andrade SF; Conrado DJ; Kulkamp IC; Guterres SS; Pohlmann AR
Eur J Pharm Sci; 2010 Aug; 40(5):441-7. PubMed ID: 20471479
[TBL] [Abstract][Full Text] [Related]
26. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
[TBL] [Abstract][Full Text] [Related]
27. [Effects of teriparatide and alendronate on bone mineral density of osteoporotic rats].
Li M; Jiao J; Meng XW; Xing XP; Xia WB; Zhou XY; Liu HC; Jiang Y; Wang O; Hu YY; Zhan ZW
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(5):335-8. PubMed ID: 15854512
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and study of alendronate derivatives as potential prodrugs of alendronate sodium for the treatment of low bone density and osteoporosis.
Vachal P; Hale JJ; Lu Z; Streckfuss EC; Mills SG; MacCoss M; Yin DH; Algayer K; Manser K; Kesisoglou F; Ghosh S; Alani LL
J Med Chem; 2006 Jun; 49(11):3060-3. PubMed ID: 16722624
[TBL] [Abstract][Full Text] [Related]
29. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
[TBL] [Abstract][Full Text] [Related]
30. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
[TBL] [Abstract][Full Text] [Related]
31. Preparation of an injectable depot system for long-term delivery of alendronate and evaluation of its anti-osteoporotic effect in an ovariectomized rat model.
Bae J; Park JW
Int J Pharm; 2015 Mar; 480(1-2):37-47. PubMed ID: 25595570
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study.
Bianchi ML; Cimaz R; Bardare M; Zulian F; Lepore L; Boncompagni A; Galbiati E; Corona F; Luisetto G; Giuntini D; Picco P; Brandi ML; Falcini F
Arthritis Rheum; 2000 Sep; 43(9):1960-6. PubMed ID: 11014345
[TBL] [Abstract][Full Text] [Related]
33. Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat.
Gasser JA; Ingold P; Venturiere A; Shen V; Green JR
J Bone Miner Res; 2008 Apr; 23(4):544-51. PubMed ID: 18072878
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
[TBL] [Abstract][Full Text] [Related]
35. Alendronate for the treatment of osteoporosis in men.
Olszynski WP; Davison KS
Expert Opin Pharmacother; 2008 Feb; 9(3):491-8. PubMed ID: 18220499
[TBL] [Abstract][Full Text] [Related]
36. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate.
Dobnig H; Stepan JJ; Burr DB; Li J; Michalská D; Sipos A; Petto H; Fahrleitner-Pammer A; Pavo I
J Bone Miner Res; 2009 Dec; 24(12):1998-2006. PubMed ID: 19453263
[TBL] [Abstract][Full Text] [Related]
37. [Effect of alendronate on bone tissue status of senescence-accelerated OXYS rats].
Muraleva NA; Sadovoĭ MA; Kolosova NG
Adv Gerontol; 2011; 24(1):143-6. PubMed ID: 21809636
[TBL] [Abstract][Full Text] [Related]
38. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
[TBL] [Abstract][Full Text] [Related]
39. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
[TBL] [Abstract][Full Text] [Related]
40. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]